Díaz-Villamarín, X.; Martínez-Pérez, M.; Nieto-Sánchez, M.T.; Ruiz-Tueros, G.; Fernández-Varón, E.; Torres-García, A.; González Astorga, B.; Blancas, I.; Iáñez, A.J.; Cabeza-Barrera, J.;
et al. Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study. Pharmaceutics 2024, 16, 956.
https://doi.org/10.3390/pharmaceutics16070956
AMA Style
Díaz-Villamarín X, Martínez-Pérez M, Nieto-Sánchez MT, Ruiz-Tueros G, Fernández-Varón E, Torres-García A, González Astorga B, Blancas I, Iáñez AJ, Cabeza-Barrera J,
et al. Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study. Pharmaceutics. 2024; 16(7):956.
https://doi.org/10.3390/pharmaceutics16070956
Chicago/Turabian Style
Díaz-Villamarín, Xando, María Martínez-Pérez, María Teresa Nieto-Sánchez, Gabriela Ruiz-Tueros, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, Antonio J. Iáñez, José Cabeza-Barrera,
and et al. 2024. "Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study" Pharmaceutics 16, no. 7: 956.
https://doi.org/10.3390/pharmaceutics16070956
APA Style
Díaz-Villamarín, X., Martínez-Pérez, M., Nieto-Sánchez, M. T., Ruiz-Tueros, G., Fernández-Varón, E., Torres-García, A., González Astorga, B., Blancas, I., Iáñez, A. J., Cabeza-Barrera, J., & Morón, R.
(2024). Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study. Pharmaceutics, 16(7), 956.
https://doi.org/10.3390/pharmaceutics16070956
